SE0401871D0 - New compositions - Google Patents
New compositionsInfo
- Publication number
- SE0401871D0 SE0401871D0 SE0401871A SE0401871A SE0401871D0 SE 0401871 D0 SE0401871 D0 SE 0401871D0 SE 0401871 A SE0401871 A SE 0401871A SE 0401871 A SE0401871 A SE 0401871A SE 0401871 D0 SE0401871 D0 SE 0401871D0
- Authority
- SE
- Sweden
- Prior art keywords
- xylose
- compositions
- novel
- new compositions
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 abstract 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract 4
- 229930182470 glycoside Natural products 0.000 abstract 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 glycoside compounds Chemical class 0.000 abstract 1
- 150000002338 glycosides Chemical class 0.000 abstract 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401871A SE0401871D0 (sv) | 2004-07-15 | 2004-07-15 | New compositions |
| PCT/SE2005/001152 WO2006006933A2 (en) | 2004-07-15 | 2005-07-14 | Antiproliferative compositions comprising aryl substituted xylopyranoside derivatives |
| EP05757818A EP1765363A2 (en) | 2004-07-15 | 2005-07-14 | New compositions |
| US11/632,273 US20080027023A1 (en) | 2004-07-15 | 2005-07-14 | Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401871A SE0401871D0 (sv) | 2004-07-15 | 2004-07-15 | New compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0401871D0 true SE0401871D0 (sv) | 2004-07-15 |
Family
ID=32867251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0401871A SE0401871D0 (sv) | 2004-07-15 | 2004-07-15 | New compositions |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080027023A1 (sv) |
| EP (1) | EP1765363A2 (sv) |
| SE (1) | SE0401871D0 (sv) |
| WO (1) | WO2006006933A2 (sv) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2349311C1 (ru) * | 2007-08-02 | 2009-03-20 | Михаил Владимирович Кутушов | Применение дериватов нафталина в качестве средств для лечения онкологических заболеваний |
| HU0800012D0 (en) * | 2008-01-10 | 2008-03-28 | Geiszt Miklos Dr | Novel use and methods for the treatment and prevention of ulcerative colitis |
| JP5491421B2 (ja) | 2008-03-04 | 2014-05-14 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス |
| WO2010148207A2 (en) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| KR101913442B1 (ko) | 2010-09-01 | 2018-10-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| BR112013004707A2 (pt) | 2010-09-01 | 2016-05-10 | Arena Pharm Inc | administração de um composto antiobesidade a indivíduos com comprometimento renal |
| SG10201506870PA (en) | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Salts of lorcaserin with optically active acids |
| SG188361A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| US20150297610A1 (en) | 2012-10-09 | 2015-10-22 | Arena Pharmaceuticals, Inc. | Method of weight management |
| CA2926480A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| JP6350987B2 (ja) * | 2014-08-04 | 2018-07-04 | 本田技研工業株式会社 | ＧＨファミリー３に属する耐熱性β―キシロシダーゼ |
| JP6364662B2 (ja) * | 2014-09-17 | 2018-08-01 | 本田技研工業株式会社 | ＧＨファミリー３に属する耐熱性β―キシロシダーゼ |
| WO2016153078A1 (en) * | 2015-03-20 | 2016-09-29 | Opiyo Sammy Oyoo | Use of suramin and arginase inhibitors in malignant neoplasia |
| US20170273926A1 (en) | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| MX390145B (es) | 2016-10-06 | 2025-03-20 | Orbus Therapeutics Inc | Formulaciones para la administracion de eflornitina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000303D0 (sv) * | 2000-01-31 | 2000-01-31 | Xylogen Ab | Novel compounds |
| IL152428A0 (en) * | 2000-04-26 | 2003-05-29 | Univ Kingston | Formulations and method of using nitric oxide mimetics against a malignant cell phenotype |
-
2004
- 2004-07-15 SE SE0401871A patent/SE0401871D0/sv unknown
-
2005
- 2005-07-14 WO PCT/SE2005/001152 patent/WO2006006933A2/en not_active Ceased
- 2005-07-14 US US11/632,273 patent/US20080027023A1/en not_active Abandoned
- 2005-07-14 EP EP05757818A patent/EP1765363A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006006933A2 (en) | 2006-01-19 |
| WO2006006933A3 (en) | 2006-03-02 |
| US20080027023A1 (en) | 2008-01-31 |
| EP1765363A2 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0401871D0 (sv) | New compositions | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| BRPI0606891A2 (pt) | anticorpos dr5 e usos dos mesmos | |
| NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| SG148169A1 (en) | Combination drug therapy to treat obesity | |
| SE0301700D0 (sv) | Novel compounds | |
| MX2009004699A (es) | Compuestos de piridinona. | |
| CY1118065T1 (el) | Καινοτομες αμινογλυκοσιδες και χρησεις αυτων στη θεραπεια γενετικων διαταραχων | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
| MX2009005011A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
| BRPI0415525A (pt) | derivados de imidazola e seu uso como agentes farmacêuticos | |
| Ghasemi et al. | Tricin isolated from Allium atroviolaceum potentiated the effect of docetaxel on PC3 cell proliferation: role of miR-21 | |
| WO2006037024A3 (en) | Salts of decitabine | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| BR112012006252A2 (pt) | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". | |
| NO20091191L (no) | Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme | |
| MX2009005293A (es) | Novedosos anticuerpos antiproliferacion. | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
| MX2007003216A (es) | Derivados y medicamentos sustituidos del cromano y su uso en terapias. | |
| ES2340502T3 (es) | Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad. | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |